None.
The death of clinical trial participant in 1999 has dampened the interest of
human gene transfer therapy. There is tremendous scrutiny from FDA
regarding this type of method. The current trend in US regarding treating
hemophilia is to provide prophylactic factor support in contrast to the
previous practice of giving factor only in the event of bleeding episode.
